Unknown News
Unknown Market News
13d
Biogen Highlights Litifilimab Lupus Data and Reports Q3 R&D Charges Amid Neuroscience Strategy Shift
- Biogen disclosed preliminary Q3 2026 R&D charges on October 15 and unveiled compelling 52‑week Phase 2 data for litifilimab in cutaneous lupus, underscoring strategic diversification.
27d
FDA Grants Biogen’s Salanersen Breakthrough Therapy Status in Major Development for SMA Pipeline
Biogen’s salanersen has received FDA Breakthrough Therapy designation for spinal muscular atrophy, paving the way for expedited Phase 3 trials.
24 Sep at 13:52
Biogen Finalizes RayThera Acquisition and Unveils Robust Q2 Results, Propelling Growth Outlook
Biogen completed its acquisition of RayThera and posted strong Q2 results led by growth drugs, supporting upgraded 2026 guidance amid pipeline momentum.
10 Sep at 13:52
Biogen Scores Two Back-to-Back Wins: LEQEMBI China Approval and Promising Dravet Syndrome Data
Biogen stock buoyed by recent LEQEMBI subcutaneous approval in China and encouraging long‑term results for Dravet syndrome therapy zorevunersen.
27 Aug at 13:52
Biogen Launches LEQEMBI IQLIK Autoinjector in U.S. and Completes RayThera Acquisition in Past Week
In the past week, Biogen (BIIB) rolled out its LEQEMBI IQLIK autoinjector for early Alzheimer’s and finalized the RayThera acquisition, reinforcing its growth pipeline.
13 Aug at 13:52
Biogen's Stock Rises Amid Strategic Developments and Market Dynamics
Biogen's stock sees a 2.68% increase following strategic moves and market trends.
03 Aug at 00:52
Strategic Acquisitions and Promising Trials: Biogen's Path Amid Market Fluctuations
Biogen Inc. (NASDAQ: BIIB) has been at the forefront of significant developments in the biotechnology sector. These events have had a notable impact on the company's stock performance, reflecting investor sentiment and market dynamics.